SPATA31E2P

Across TCGA pan-cancer cohorts, SPATA31E2P RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated SPATA31E2P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher SPATA31E2P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA31E2P expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

CHOL, STAD, and OV are the cancer types where SPATA31E2P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.024	0.728	<.001	108	view →
STAD	DFS	Tertile	II,III,IV	0.278	0.719	<.001	75	view →
OV	DFS	Tertile	III,IV	0.369	0.146	.016	42	view →
CESC	OS	Tertile	All	0.121	0.591	.003	36	view →
KIRP	DFS	Tertile	II,III,IV	0.038	0.783	<.001	36	view →
SKCM	OS	Tertile	All	0.656	0.301	.026	27	view →
KIRC	DFS	Tertile	III,IV	0.180	0.642	.005	18	view →
PCPG	OS	Tertile	All	0.571	0.963	<.001	18	view →
LIHC	OS	Tertile	II,III,IV	0.178	0.695	.010	18	view →
THCA	DFS	Tertile	II,III,IV	0.445	0.768	.018	9	view →
HNSC	OS	Tertile	III,IV	1.000	0.320	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

SPATA31E2P–CHOL (OS)

Open the CHOL breakdown →